Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) Enterprise Value: 2022-2025

Historic Enterprise Value for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $594.2 million.

  • Taysha Gene Therapies' Enterprise Value rose 134.14% to $594.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.5 million, marking a year-over-year increase of 113.00%. This contributed to the annual value of $192.6 million for FY2024, which is 3.26% up from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' Enterprise Value is $594.2 million, which was up 225.40% from $182.6 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Enterprise Value registered a high of $594.2 million during Q3 2025, and its lowest value of -$12.8 million during Q1 2023.
  • For the 3-year period, Taysha Gene Therapies' Enterprise Value averaged around $229.5 million, with its median value being $192.6 million (2024).
  • Its Enterprise Value has fluctuated over the past 5 years, first plummeted by 108.44% in 2023, then surged by 9,334.57% in 2024.
  • Over the past 4 years, Taysha Gene Therapies' Enterprise Value (Quarterly) stood at $53.2 million in 2022, then soared by 250.36% to $186.5 million in 2023, then grew by 3.26% to $192.6 million in 2024, then spiked by 134.14% to $594.2 million in 2025.
  • Its last three reported values are $594.2 million in Q3 2025, $182.6 million for Q2 2025, and $432.5 million during Q1 2025.